Acrivon Therapeutics, Inc. Common Stock (ACRV)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	43.61 mm	43.61 mm	43.61 mm	43.61 mm	43.61 mm	43.61 mm
Cash burn (monthly)	938.67 k	(no burn)	8.38 mm	7.11 mm	5.77 mm	5.06 mm
Cash used (since last report)	4.99 mm	n/a	44.54 mm	37.78 mm	30.69 mm	26.88 mm
Cash remaining	38.62 mm	n/a	-933.12 k	5.83 mm	12.92 mm	16.73 mm
Runway (months of cash)	41.1	n/a	-0.1	0.8	2.2	3.3

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

ACRV institutional ownership history Ownership history

94.2% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	63	57	+10.5%
Opened positions	12	8	+50.0%
Closed positions	6	8	-25.0%
Increased positions	18	17	+5.9%
Reduced positions	15	14	+7.1%

13F shares	Current	Prev Q	Change
Total value	139.70 bn	160.53 bn	-13.0%
Total shares	29.34 mm	29.06 mm	+1.0%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Ra Capital Management	8.34 mm	$50.21 bn	0.0%
Perceptive Advisors	5.36 mm	$32.27 bn	0.0%
Chione	3.85 mm	$22.55 mm	0.0%
Sands Capital Ventures	2.12 mm	$12.78 bn	0.0%
Citadel Advisors	2.12 mm	$12.76 bn	-1.0%
Sands Capital Life Sciences Pulse Fund II	1.65 mm	$27.50 mm	0.0%
BlackRock	945.50 k	$5.69 bn	+20.1%
Wellington Management	888.13 k	$5.35 bn	0.0%
Vanguard	671.63 k	$4.04 bn	+5.3%
Marshall Wace	597.79 k	$3.60 bn	-26.2%

Largest transactions	Shares	Bought/sold	Change
Acorn Capital Advisors	405.24 k	+405.24 k	NEW
Marshall Wace	597.79 k	-212.07 k	-26.2%
BlackRock	945.50 k	+158.51 k	+20.1%
Exome Asset Management	0.00	-116.76 k	EXIT
Millennium Management	0.00	-39.75 k	EXIT
GS The Goldman Sachs Group, Inc.	237.55 k	+39.38 k	+19.9%
Prelude Capital Management	0.00	-37.73 k	EXIT
Vanguard	671.63 k	+34.09 k	+5.3%
Ubs Oconnor	102.78 k	+23.54 k	+29.7%
Citadel Advisors	2.12 mm	-20.98 k	-1.0%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

ACRV insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
1 Mar 25	Eric Devroe	Stock Option Common Stock	Grant	Acquire A	No	No	5.31	140,540	746.27 k	140,540
1 Mar 25	Erick Gamelin	Stock Option Common Stock	Grant	Acquire A	No	No	5.31	78,078	414.59 k	78,078
1 Mar 25	Rasmus Holm-Jorgensen	Stock Option Common Stock	Grant	Acquire A	No	No	5.31	109,309	580.43 k	109,309
1 Mar 25	Mary Miller	Stock Option Common Stock	Grant	Acquire A	No	No	5.31	93,693	497.51 k	93,693
1 Mar 25	Katharine Peterson	Stock Option Common Stock	Grant	Acquire A	No	No	5.31	31,900	169.39 k	31,900

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Cantor Fitzgerald Initiates Coverage On Acrivon Therapeutics with Overweight Rating

31 Jan 25

Cantor Fitzgerald analyst Li Watsek initiates coverage on Acrivon Therapeutics (NASDAQ:ACRV) with a Overweight rating.